Objectives: To provide guidance for agency planning by identifying barriers faced by Korean pharmaceutical companies in global regulatory affairs. Methods: A questionnaire survey on global regulatory affairs was administered by email to personnel at Korean pharmaceutical companies. From a total of 60, 28 responses were collected. Respondents’ companies were classified as small-sized or large-sized, based on whether their annual sales amounted to KRW 100 billion. Results: Small-sized companies were experiencing greater difficulties in receiving drug approvals from advanced countries, particularly during the Investigational New Drug (IND) and Good Manufacturing Practice (GMP) processes. Conclusions: Support measures to specifically help small-sized companies enter more advanced markets and further improved global regulatory guidelines that can meet large-sized companies’ expectations are needed. Moreover, domestic and global regulatory standards should be harmonized to benefit both groups.
목차
Ⅰ. 서론 1. 연구배경 2. 연구목적 Ⅱ. 연구방법 1. 연구대상 및 자료수집 방법 2. 설문 구성 및 조사내용 3. 자료 분석 방법 Ⅲ. 연구결과 1. 제약기업재직자의 특성 2. 지역별 허가 성공 비율 및 실패 요인 분석 3. 의약품 해외 인허가 단계별 애로사항 분석 4. 구체적 해결과제와 지원방안 Ⅳ. 고찰 Ⅴ. 결론 REFERENCES